Tech Company Financing Transactions
Profectus BioSciences Funding Round
Profectus BioSciences, operating out of Baltimore, secured $3 million from Cross Atlantic Capital Partners.
Transaction Overview
Company Name
Announced On
5/31/2006
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Series A
Investors
Cross Atlantic Capital Partners (Lead Investor)
Proceeds Purpose
The new financing will be used to start clinical trials later this year on potential treatments developed from this technology
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
6411 Beckley St.
Baltimore, MD 21224
USA
Baltimore, MD 21224
USA
Phone
Website
Email Address
Overview
Profectus BioSciences, Inc. identifies and commercializes technologies intended to reduce the morbidity and mortality caused by viral diseases, especially Human Immunodeficiency Virus (HIV).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Thomas Paese
Chief Operating Officer
Jeffrey Meshulam
Chief Scientific Officer
John Eldridge
VP - Operations
Terry Higgins
Browse more venture capital transactions:
Prev: 5/31/2006: FoldRx Pharmaceuticals venture capital transaction
Next: 5/31/2006: Breach Security venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs